Compare Stocks → This 1 Biotech Stock has been shocking the markets (From Huge Alerts) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:IMPLNASDAQ:KLDOTSE:PLINASDAQ:SNSE Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMPLImpel Pharmaceuticals$0.27$0.02▼$4.20$956K1.17682,655 shs720,000 shsKLDOKaleido Biosciences$0.00$0.00$0.00▼$0.25$4K-0.063,654 shs2,240 shsPLIProMetic Life SciencesC$13.60C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsSNSESensei Biotherapeutics$1.51-3.8%$1.11$0.51▼$1.94$37.87M0.14134,803 shs148,265 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMPLImpel Pharmaceuticals0.00%0.00%0.00%0.00%-98.35%KLDOKaleido Biosciences0.00%0.00%0.00%0.00%-50.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%SNSESensei Biotherapeutics-14.67%-4.85%+42.73%+85.14%+1.29%Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics4.6429 of 5 stars3.55.00.04.82.01.71.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMPLImpel PharmaceuticalsN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/ASNSESensei Biotherapeutics3.00Buy$4.00164.90% UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMPLImpel Pharmaceuticals$20.99M0.00N/AN/A($1.86) per share0.00KLDOKaleido Biosciences$1.10M0.00N/AN/AN/A∞PLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00SNSESensei BiotherapeuticsN/AN/AN/AN/A$2.60 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMPLImpel Pharmaceuticals-$106.31M-$3.13N/AN/AN/A-353.93%N/A-127.43%N/AKLDOKaleido BiosciencesN/A-$2.24N/AN/AN/AN/AN/AN/AN/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ASNSESensei Biotherapeutics-$34.10M-$1.22N/AN/AN/AN/A-44.01%-38.58%8/1/2024 (Estimated)Latest NCYT, SNSE, KLDO, IMPL, and PLI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/28/2024Q4 2023SNSESensei Biotherapeutics-$0.32-$0.30+$0.02-$0.30N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMPLImpel PharmaceuticalsN/AN/AN/AN/AN/AKLDOKaleido BiosciencesN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ASNSESensei BiotherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMPLImpel PharmaceuticalsN/A0.190.13KLDOKaleido BiosciencesN/AN/AN/APLIProMetic Life Sciences37.474.063.66SNSESensei Biotherapeutics0.0111.9211.92OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMPLImpel Pharmaceuticals73.88%KLDOKaleido Biosciences81.56%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics10.50%Insider OwnershipCompanyInsider OwnershipIMPLImpel Pharmaceuticals6.20%KLDOKaleido Biosciences9.00%PLIProMetic Life SciencesN/ASNSESensei Biotherapeutics25.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableIMPLImpel Pharmaceuticals16023.90 million22.42 millionNot OptionableKLDOKaleido Biosciences7642.62 million38.79 millionNot OptionablePLIProMetic Life Sciences48723.31 millionN/ANot OptionableSNSESensei Biotherapeutics2825.08 million18.69 millionNot OptionableNCYT, SNSE, KLDO, IMPL, and PLI HeadlinesSourceHeadlineSNSE Stock Earnings: Sensei Biotherapeutics Misses EPS for Q1 2024investorplace.com - May 9 at 2:11 PMSensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlightsglobenewswire.com - May 9 at 7:30 AMSensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meetingglobenewswire.com - April 24 at 4:05 PMSensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conferenceglobenewswire.com - April 9 at 7:30 AMSensei Biotherapeutics CFO Erin Colgan to resignuk.investing.com - April 4 at 11:42 PMSensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironmentglobenewswire.com - April 4 at 4:05 PMSensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposiumglobenewswire.com - March 22 at 7:30 AMSensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferencesglobenewswire.com - March 6 at 7:30 AMBuy Rating Affirmed for Sensei Biotherapeutics on Strong Fiscal Health and Promising Clinical Trialsmarkets.businessinsider.com - February 29 at 3:22 PMSensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlightsglobenewswire.com - February 28 at 7:30 AMSensei Biotherapeutics Announces Board Member Resignation and Consultant Rolemsn.com - February 9 at 10:35 AMSensei Biotherapeutics Streamlines Board, Appoints Interim Chairmsn.com - February 9 at 10:35 AMSensei Biotherapeutics to Present at Upcoming Conferencesfinance.yahoo.com - February 7 at 7:42 AMBuy Rating Affirmed for Sensei Biotherapeutics Amidst Promising SNS-101 Clinical Progress and Favorable Safety Datamarkets.businessinsider.com - January 6 at 1:14 AMSensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestonesfinance.yahoo.com - January 4 at 8:07 AMThe Potential Rise in the Price of Sensei Biotherapeutics Inc (SNSE) following insiders activityknoxdaily.com - January 1 at 9:39 AMAnalysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Praxis Precision Medicines (PRAX) and Sensei Biotherapeutics (SNSE)markets.businessinsider.com - December 4 at 10:40 PMHC Wainwright & Co. Initiates Coverage of Sensei Biotherapeutics (SNSE) with Buy Recommendationmsn.com - December 4 at 10:40 PMKeeping an Eye on Sensei Biotherapeutics Inc (SNSE) After Insider Trading Activityknoxdaily.com - November 7 at 2:19 PMSensei Biotherapeutics GAAP EPS of -$0.28 in-linemsn.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlightsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Inc (SNSE) Reports Q3 2023 Financial Resultsfinance.yahoo.com - November 7 at 9:19 AMSensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - November 3 at 8:51 PMSensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meetingfinance.yahoo.com - October 25 at 2:01 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up It’s Time to Buy Into the Super Micro Computer Stock ImplosionApril 22, 2024 12:33 PMView It’s Time to Buy Into the Super Micro Computer Stock ImplosionAll Headlines Company DescriptionsImpel PharmaceuticalsNASDAQ:IMPLImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Kaleido BiosciencesNASDAQ:KLDOKaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.ProMetic Life SciencesTSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.Sensei BiotherapeuticsNASDAQ:SNSESensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.